Printer Friendly

ALTANA Pharma U.S. Appoints Mark Salyer Senior Vice President of Sales and Marketing.

FLORHAM PARK, N.J. -- ALTANA Pharma U.S. today announced the appointment of Mark Salyer as Senior Vice President of Sales and Marketing. Mr. Salyer will be responsible for new product launches, market development, and strategic planning for the company as it brings its promising pipeline of respiratory and gastrointestinal products to market.

"Mark's significant marketing experience and his broad knowledge of the respiratory markets in particular will be a major asset to us as we develop our new products," said George Cole, president, ALTANA Pharma U.S.

Mr. Salyer comes to ALTANA Pharma U.S. after a 17-year career at GlaxoSmithKline, where he most recently served as Global Commercial Strategy Vice President for the company's respiratory products based in London. In that role, he was responsible for global commercial strategy for current and pipeline products, making it GlaxoSmithKline's most promising product portfolio. Among his other positions at GlaxoSmithKline, he served as the director of marketing of the company's allergy, cardiovascular, asthma, chronic obstructive pulmonary disease and migraine brands in the United States. Mark has a MBA from Duke University.


ALTANA Pharma, formerly Byk Gulden, is an international pharmaceutical company focused primarily on respiratory and gastrointestinal treatments. The company had pharmaceutical sales of $1.4 billion USD in 2001. Its U.S.-based operations, headquartered in Florham Park, New Jersey, were established in 2002. A research-driven pharmaceutical company, ALTANA Pharma invests almost 20 percent of pharmaceutical sales into research. The company's rich history of drug development includes the discovery of the blockbuster proton pump inhibitor pantoprazole, marketed in the United States by Wyeth-Ayerst as Protonix. Going forward, ALTANA Pharma's U.S. operations will market the products developed in its research facilities. ALTANA Pharma's parent company is ALTANA AG, based in Bad Homburg, Germany.


CONTACT: Jennifer Horowitz of GCI Healthcare, +1-212-537-8126,, for ALTANA Pharma U.S.
COPYRIGHT 2002 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 23, 2002
Previous Article:New Study Shows Topamax(R) Can Reduce Frequency of Migraine Headaches; Preventive Treatment Targets Chronic Sufferers of One of World's Most...
Next Article:FDA Approves Gilead's Hepsera(TM) for the Treatment of Chronic Hepatitis B; - First Nucleotide Analogue for the Treatment of Chronic Hepatitis B -.

Related Articles
GPC Biotech Announces Expansion of Collaboration with ALTANA Pharma to Include LeadCode(TM); -- Collaboration to Establish U.S. ALTANA Research...
GPC Biotech Announces Achievement of New Milestones in Collaboration with ALTANA Pharma's U.S. Division, ALTANA Research Institute; Milestones...
GPC Biotech Achieves Milestones Totaling $1.5 Million in Collaboration with ALTANA to Build U.S. ALTANA Research Institute.
ALTANA Pharma U.S. Appoints Roberto Cetrullo Vice President, Business Development.
ALTANA Pharma U.S. Appoints Tushar P. Shah, M.D. Senior Vice President, Scientific and Clinical Affairs.
Ventiv Health Successfully Deploys Target SFA; Target Mobile Laptop Software Rolled Out for Nearly 300 Altana Reps.
ALTANA Pharma Joins Forces With the U.S. COPD Coalition to Confront The Growing Problem of Chronic Obstructive Pulmonary Disease (COPD).
Evotec OAI Successfully Completes Assay Development Programme with ALTANA Pharma AG.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters